Occupational Therapists in Milford, NE Accepting Medicare
5 Occupational Therapists found. Showing 1 - 5
 Dr. Megan Andersen, OTD Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 610 224th, Milford, NE 68405 Phone: 402-761-3230 |
Kelly Lynn Little, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1100 1st St, Milford, NE 68405 Phone: 402-761-2261 |
Mrs. Jennifer L A Streeter, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 610 224th Road, Sunrise Country Manor, Milford, NE 68405 Phone: 402-761-3230 Fax: 402-761-3133 |
Jan Harris, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Rr 2 Box A, Milford, NE 68405 Phone: 402-761-3230 |
Meredith Ann Kohout, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 610 224th, Milford, NE 68405 Phone: 402-761-3230 |
News Archive
Rosetta Genomics and AXA Diagnostics sign exclusive distribution agreement
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, and AXA Diagnostics, a privately owned company that markets specialized diagnostic tests, announced today the signing of an exclusive distribution agreement in Italy for Rosetta Genomics' three currently available diagnostic tests.
Notice of Allowance issued by PTO for OSI's EGFR drug
OSI Pharmaceuticals, Inc. announced today that the U.S. Patent & Trademark Office has issued a "Notice of Allowance" in OSI's reissue application for U.S. Patent No.5,747,498 (the ‘498) composition of matter patent for Tarceva® (erlotinib). The reissued patent will replace the original ‘498 patent and have the same November 2018 expiration date.
Portrait of newly insured takes shape
Early enrollees in the health law's marketplaces were more likely to use expensive specialty drugs and less likely to use contraceptives, according to an analysis of two months of drug claims data by Express Scripts. A Rand analysis, meanwhile, argues that most of the newly insured signed up with an employer rather than buying it through the marketplaces.
Novogen granted Canadian patent for health supplements for the treatment of menopause symptoms
Pharmaceutical company, Novogen, has been granted patent coverage over its OTC products being sold in Canada. The patent covers the isoflavone composition of the products Promensil(TM), Rimostil(TM) and Trinovin(TM).
FDA approves Tysabri to treat Crohn's disease
The U.S. Food and Drug Administration has approved Tysabri (natalizumab) for the treatment of moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies.
› Verified 5 days ago
Speech-Language Pathologists
Occupational Therapists
Chiropractors
Physical Therapists